FdaApplication
NDA 210807
Identifiers
- fda_app_no: NDA210807
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC |
| application_type | NDA |
| approval_date | 2018-08-30 |
Revenue by product
DELSTRIGO
| Period | Revenue |
|---|---|
| Q2 2026 | $101.0M* |
| Q1 2026 | $75.0M* |
| Q4 2025 | $78.0M* |
| Q3 2025 | $77.0M* |
| Q2 2025 | $83.0M* |
| Q1 2025 | $67.0M* |
| Q4 2024 | $69.0M* |
| Q3 2024 | $65.0M* |
| Q2 2024 | $60.0M* |
| Q1 2024 | $56.0M* |
| Q4 2023 | $53.0M* |
| Q3 2023 | $54.0M* |
| Q2 2023 | $50.0M* |
| Q1 2023 | $44.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| DELSTRIGO | DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE | 100MG;300MG;300MG | TABLET;ORAL |
1 product